ClinicalTrials.gg
RecruitingNCT07717268OLIGORESISTUpdated Jul 21, 2026

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

A Phase 2 interventional study of Xtandi and Zytiga® (Abiraterone Acetate) in Prostatic Neoplasms, Castration-Resistant, sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic. Recruiting at 15 sites in Spain. Open to male participants. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled May 2024, registered Jul 2026).
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Prostatic Neoplasms, Castration-Resistant with a site in Spain — 10 open to participants now, 15 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Spain.

Planned enrollment
18th of 21
51 · median 180
Started
2024
with 3 others
Phase 2
5 of 21
1 open now
Primary completion
2030-05
later than 13 of 14 live
Registered
21st of 21
by date
Lead sponsor
1 of 21
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Among the 21 studies in Prostatic Neoplasms, Castration-Resistant with a site in Spain, this one is the 18th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 2, reaches primary completion later than 13 of the 14 other live ones, and was the 21st registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

10 of the 21 studies in Prostatic Neoplasms, Castration-Resistant with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Prostatic Neoplasms, Castration-Resistant with a site in Spain, or all of them as a file.
02

Study summary

The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant prostate cancer in oligometastasis (≤5).

Hence, the investigators evaluate the results of the combination of two widely used treatments in prostate cancer: SBRT plus the 'standard of care' for patients with mCRPC, second-generation antiandrogens (abiraterone and enzalutamide).

Primary objective: Determine the PRFS measured from the time of initiation of second-generation antiandrogen to the time of radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.

Secondary objectives:

  • Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.
  • Quality of life of these patients using the European Organization for Research and Treatment of Cancer (EORTC) quality of life scale, EORTC QLQ-C30, validated for oncology patients.
  • Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale.

This is a phase II, multicenter, prospective, single group study in patients with castrate-resistant prostate cancer (CRPC).

Patients will be recruited at the participant sites, after study approval and hospital authorization.

51 patients will be included in the study. Eligible patients will require:

  • Choline PET/CT or 68Ga-PSMA PET/CT, dated no more than 8 weeks prior to inclusion.
  • Clinical history, physical examination and functional evaluation scale (ECOG).
  • Geriatric assessment scale for patients > 75 years (modified G8 scale)
  • Toxicity scale assessment (CTCAEv5.0)
  • Baseline quality of life questionnaire (EORTC QLQ-C30) (47)
  • Blood tests with complete blood count, coagulation, liver function, renal function, ions, alkaline phosphatase, PSA and total and free testosterone, dated no more than 4 weeks prior inclusion.
  • Inclusion/exclusion criteria assessment
  • Second generation antiandrogen prescription, chosen by the responsible physician according to clinical practice, in each case.

Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus). SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus.

Recruitment time is estimated at 36 months and a total follow-up time of 36 months. The total duration of the trial is therefore expected to be 6 years, to allow complete follow-up of the last patients included.

03

Conditions studied

  • Prostatic Neoplasms, Castration-Resistant

Keywords

  • Fractionated stereotactic radiotherapy
  • second-generation antiandrogen
  • Phase II
  • castration-resistant prostate cancer
  • oligometastatic patients
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologically prostate adenocarcinoma, confirmed with a .
  • Testosterone in biochemical castration ranges (testosterone \<50 ng/ml or 1.7 nmol/L) and documented progression: biochemical according to Phoenix criteria or distant by radiological confirmation (PSMA PET/CT or Choline PET/CT)
  • Biochemistry progression confirmed according to Phoenix criteria, with testosterone in castration levels (testosterone \<50 ng/ml or 1.7 nmol/L).
  • Radiological confirmation (with choline-PET/CT or 68Ga-PSMA-PET/CT) of ≤5 node or bone , non-visceral, eligible to receive SBRT treatment (\< 3 cm major diameter in bone metastases, \< 5 cm in lymph node metastases). In the case of very close metastases, a limit of up to 5 treatment fields with SBRT is allowed, instead of 5 metastases.
  • Patients candidate to receive treatment with abiraterone or enzalutamide as per clinical routine, and treatment selection and prescription assigned by responsible physician before the inclusion in the study. or or who has started treatment no more than 14 days prior to signing, as treatment after a diagnosis of oligoresistance.
  • Patients must provide written .
  • > 3 months.

Exclusion criteria

Exclusion Criteria:

  • Patients with prostate carcinoma with histology other than adenocarcinoma.
  • No previous .
  • > 5 , not approachables in 5 treatment fields
  • Patients with visceral metastasis and or metastasis non elegible to receive SBRT.
  • Patients with Testosterone above castration levels
  • Patients with prior treatment with docetaxel as CRPC treatment (previous docetaxel treatment is permitted when administered as hormone-sensitive metastatic prostate cancer treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Other
    Second generation antiandrogen plus SBRT

    Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus). SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus

    Drug: Xtandi · Drug: Zytiga® (Abiraterone Acetate) · Radiation: SBRT

Interventions

  • DrugEnzalutamideStudies of EnzalutamideEnzalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus)

  • DrugAbiraterone AcetateStudies of Abiraterone AcetateAbiraterone Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each patient will be included in the study once the second generation antiandrogen is initiated (which will be maintained until radiological progression, suspension due to poor tolerance and/or exitus)

    Also known as: abiraterone acetate

  • RadiationSBRT

    SBRT will be performed at least 2 weeks after initiating treatment with second generation antiandrogen, without exceeding 8 weeks from the start of treatment, and follow-up will continue up to a maximum of 36 months after completion of SBRT and/or exitus

06

What researchers measure

Primary outcomes

  1. Determine the PRFS

    Determine the PRFS measured from the time of initiation of second-generation antiandrogen to the time of radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen

    Time frame: From the start of the study (the day it begins) or up to 14 days before the start of the study (corresponding to the start of treatment with second-generation antiandrogens) until the time of radiological progression during follow-up, it can be up to 36.

Secondary outcomes

  1. Overall survival

    Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.

    Time frame: From the start of second-generation antiandrogen therapy (at baseline or up to 14 days prior) to the date of death from any cause, assessed up to 36 months.

  2. Quality of life by EORTC scale

    QoL using the European Organization for Research and Treatment of Cancer (EORTC) quality of life scale, EORTC QLQ-C30, validated for oncology patients. The scale converts all scores to a standardized range from 0 (minimum) to 100 (maximum). A high score indicates a better outcome (high quality of life and good health).

    Time frame: from recruitment to the end of patient follow-up (up to 36 months)

  3. Acute and chronic toxicity

    Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale

    Time frame: from recruitment to the end of patient follow-up (up to 36 months)

07

Study locations

6 of 15 sites recruiting
  • Hospital Universitario Miguel Servet
    Zaragoza, Aragon 50009, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Clinic de Barcelona
    Barcelona, Barcelona 08036, Spain
    Recruiting
    • Joel Mases, MD · Contactmases@clinic.cat
    • Joel Mases i Rosinés, MD · Principal investigator
    • Elías Gomís, MD · Sub investigator
    • Sara Moreno, MD · Sub investigator
    • Gerard Meca, MD · Sub investigator
  • Instituto Catalán de Oncología Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
  • Hospital Universitario Basurto
    Bilbao, Basque Country 48013, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Universitario De Salamanca
    Salamanca, Castille and León 37007, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Clínico Universitario De Valladolid
    Valladolid, Castille and León 47003, Spain
    Recruiting
  • Hospital De La Santa Creu I Sant Pau
    Barcelona, Catalonia 08041, Spain
    Recruiting
    • Gemma Sancho Pardo, MD · Contactgsancho@santpau.cat · +34 935537756
    • Saudy Peláez Bonilla, Study coordinator · ContactSPelaez@santpau.cat · +34 935537760
    • Arantxa Mera Errasti, MD · Sub investigator
    • Gemma Sancho Pardo, MD · Principal investigator
    • Laura Montezuma Niño, MD · Sub investigator
    • Ana Maria Soto Cambres, MD · Sub investigator
  • Consorci Sanitari De Terrassa
    Terrassa, Catalonia 08227, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Complexo Hospitalario Universitario De Santiago
    Santiago de Compostela, Galicia 15706, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Ramón y Cajal
    Madrid, Madrid 28034, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • Noelia Sanmamed, MD · Contactnoelia.sanmamed@salud.madrid.org · +34 985 10 80 00
    • Noelia Sanmamed Salgado, MD · Principal investigator
    • Manuel Gonzalo Vázquez Masedo, MD · Sub investigator
    • Miren Gaztañaga Boronat, MD · Sub investigator
    • Maria Nieves Cabrera Martin, MD · Sub investigator
    • Natalia Vidal Cassinello, MD · Sub investigator
    • Anxela Doval Gonzalez, MD · Sub investigator
    • Javier Puente Vazquez, MD · Sub investigator
    • Ignacio Moreno, MD · Sub investigator
  • Hospital Universitario de Navarra (HUN)
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Marta Barrado Los Arcos, MD · Contactmarta.barrado.losarcos@navarra.es · +34 848 42 84 82
    • Marta Barrado Los Arcos, MD · Principal investigator
    • Amaya Sola Galarza, MD · Sub investigator
    • Elena Villafranca Iturre, MD · Sub investigator
    • Ignacio Visus Fernandez de Manzanos, MD · Sub investigator
    • Nuria Bultó Boque, MD · Sub investigator
    • Xabier Gurutzeaga Peleato, MD · Sub investigator
  • Hospital Universitario Central De Asturias
    Oviedo, Principality of Asturias 33011, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Universitario y Politécnico de La Fe
    Valencia, Valencia 46026, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Hospital de Cruces
    Barakaldo, Vizcaya 48903, Spain
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Publications

  • Shabason JE, Minn AJ. Radiation and Immune Checkpoint Blockade: From Bench to Clinic. Semin Radiat Oncol. 2017 Jul;27(3):289-298. doi: 10.1016/j.semradonc.2017.03.002. Epub 2017 Mar 16. PubMed 28577836 ↗
  • Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014 Aug;31(6):735-48. doi: 10.1007/s10585-014-9664-3. Epub 2014 Jun 27. PubMed 24968866 ↗
  • Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013 Nov;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25. PubMed 24135135 ↗
  • Reese AS, Feigenberg SJ, Husain A, Webb TJ, Hausner PF, Edelman MJ, Feliciano J, Tkaczuk KH, Sharma NK. Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. Mol Cell Pharmacol. 2013 Jan 1;5(1):19-25. PubMed 25126157 ↗
  • Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009 Jul 16;114(3):589-95. doi: 10.1182/blood-2009-02-206870. Epub 2009 Apr 6. PubMed 19349616 ↗
  • Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e597-605. doi: 10.1016/j.ijrobp.2012.03.009. Epub 2012 May 19. PubMed 22608954 ↗
  • Conde-Moreno AJ, Lopez-Guerra JL, Macias VA, Vazquez de la Torre ML, Samper Ots P, San Jose-Maderuelo S, Pastor Peidro J, Lopez-Torrecilla J, Exposito-Hernandez J. Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. Clin Transl Oncol. 2016 Apr;18(4):342-51. doi: 10.1007/s12094-015-1383-y. Epub 2015 Sep 2. PubMed 26329294 ↗
  • Lopez-Campos F, Cacicedo J, Counago F, Garcia R, Leaman-Alcibar O, Navarro-Martin A, Perez-Montero H, Conde-Moreno A. SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clin Transl Oncol. 2022 Feb;24(2):215-226. doi: 10.1007/s12094-021-02695-6. Epub 2021 Oct 11. PubMed 34633602 ↗
  • Perez-Calatayud MJ, Conde-Moreno AJ, Celada-Alvarez FJ, Rubio C, Lopez-Campos F, Navarro-Martin A, Arribas L, Santos M, Lopez-Torrecilla J, Perez-Calatayud J. SEOR SBRT-SG survey on SRS/SBRT dose prescription criteria in Spain. Clin Transl Oncol. 2021 Sep;23(9):1794-1800. doi: 10.1007/s12094-021-02583-z. Epub 2021 Mar 17. PubMed 33730312 ↗
  • Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. doi: 10.1118/1.3438081. PubMed 20879569 ↗
  • Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014 Sep 10;32(26):2902-12. doi: 10.1200/JCO.2014.55.9567. Epub 2014 Aug 11. PubMed 25113765 ↗
  • Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014 Dec 1;32(34):3824-30. doi: 10.1200/JCO.2014.56.7412. Epub 2014 Oct 27. PubMed 25349291 ↗
  • Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8-10. doi: 10.1200/JCO.1995.13.1.8. No abstract available. PubMed 7799047 ↗
  • Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050. PubMed 28404761 ↗
  • Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9. doi: 10.1093/annonc/mds232. No abstract available. PubMed 22997442 ↗
  • Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nole F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. PubMed 30738780 ↗
  • Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 Jun 20;41(18):3352-3362. doi: 10.1200/JCO.22.02394. Epub 2023 Mar 30. PubMed 36996380 ↗
  • Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28. PubMed 27477525 ↗
  • Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9. PubMed 32527692 ↗
  • Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6. PubMed 24647231 ↗
  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. PubMed 25601341 ↗
  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1. PubMed 24881730 ↗
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. PubMed 23228172 ↗
  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. PubMed 22894553 ↗
  • de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. PubMed 21612468 ↗
  • Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. PubMed 21995694 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for May 2030, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 21, 2026
StartActual
May 16, 2024
Primary completionEst.
May 16, 2030
CompletionEst.
May 16, 2030
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717268
Lead sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Collaborators
Fundacion Miguel Servet
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
May 16, 2024
Primary completion
May 16, 2030 (estimated)
Completion
May 16, 2030 (estimated)
Last update
Jul 21, 2026

Study contacts

Pablo Raña Diez, PhD
Contact
investigacion@seor.es
+34 696633409
Cristina Gutierrez Povedano, PhD
Contact
cristina.gutierrez.povedano@navarra.es
+34 675039150
Marta Barrado Los Arcos, MD
principal investigator · Hospital of Navarra

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzalutamide · Abiraterone Acetate

Start the discussion